The Cytoprotective Role of Autophagy in Response to BRAF-Targeted Therapies.
The Cytoprotective Role of Autophagy in Response to BRAF-Targeted Therapies.
复制标题
DOI：
10.3390/ijms241914774
复制
发表时间：
2023-09-30
影响因子：
5.6
通讯作者：
中科院分区：
文献类型：
--
作者：
BRAF靶向疗法广泛用于治疗具有BRAF V600突变的黑色素瘤患者。维罗非尼、达拉非尼以及恩可非尼已经证明了显著的治疗活性;然而，与其他化疗剂一样，频繁的耐药性发展限制了它们的功效。自噬是一种可能导致BRAF抑制剂耐药性的肿瘤存活机制，多项研究支持维罗非尼诱导的和达拉非尼诱导的自噬与肿瘤细胞存活之间的关联。临床试验也证明了将自噬抑制作为辅助治疗的潜在益处。对与BRAF抑制剂诱导的自噬作用相关的科学文献的综述支持自噬靶向或调节可能是有效的辅助治疗的前提。
BRAF-targeted therapies are widely used for the treatment of melanoma patients with BRAF V600 mutations. Vemurafenib, dabrafenib as well as encorafenib have demonstrated substantial therapeutic activity; however, as is the case with other chemotherapeutic agents, the frequent development of resistance limits their efficacy. Autophagy is one tumor survival mechanism that could contribute to BRAF inhibitor resistance, and multiple studies support an association between vemurafenib-induced and dabrafenib-induced autophagy and tumor cell survival. Clinical trials have also demonstrated a potential benefit from the inclusion of autophagy inhibition as an adjuvant therapy. This review of the scientific literature relating to the role of autophagy that is induced in response to BRAF-inhibitors supports the premise that autophagy targeting or modulation could be an effective adjuvant therapy.
登录
查看更多内容
影响因子：
9.7
作者：
Hartman, Mariusz L.;Gajos-Michniewicz, Anna;Czyz, Malgorzata
通讯作者：
Czyz, Malgorzata
影响因子：
4.8
作者：
Huang, Shengbing;Yang, Zhineng J.;Sinicrope, Frank A.
通讯作者：
Sinicrope, Frank A.
DOI：
10.1038/nrd4140
发表时间：
2013-11
期刊：
Nature reviews. Drug discovery
影响因子：
--
作者：
Ling H;Fabbri M;Calin GA
通讯作者：
Calin GA
影响因子：
3.1
作者：
Elshazly, Ahmed M.;Nguyen, Tuong Vi V.;Gewirtz, David A.
通讯作者：
Gewirtz, David A.
影响因子：
4
作者：
Lugowska I;Koseła-Paterczyk H;Kozak K;Rutkowski P
通讯作者：
Rutkowski P